ACRIVON THERAPEUTICS INC. - COMMON STOCK
8.8900
17-May-24 14:59:54
15 minutes delayed
Stocks
+0.3300
+3.86%
Today's range
8.5650 - 9.0000
ISIN
N/A
Source
NASDAQ
-
Acrivon Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
14 May 2024 07:00:00 By Nasdaq GlobeNewswire
-
24 Apr 2024 15:01:00 By Nasdaq GlobeNewswire
-
10 Apr 2024 07:00:00 By Nasdaq GlobeNewswire
-
Acrivon Therapeutics Announces $130 Million Private Placement Financing
09 Apr 2024 06:00:00 By Nasdaq GlobeNewswire
-
28 Mar 2024 07:00:00 By Nasdaq GlobeNewswire
-
04 Mar 2024 07:00:00 By Nasdaq GlobeNewswire
-
27 Feb 2024 07:00:00 By Nasdaq GlobeNewswire
-
08 Feb 2024 07:00:00 By Nasdaq GlobeNewswire
-
Acrivon Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
06 Feb 2024 07:00:00 By Nasdaq GlobeNewswire
-
Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12 Jan 2024 15:00:24 By Nasdaq GlobeNewswire
-
Acrivon Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
04 Jan 2024 07:00:01 By Nasdaq GlobeNewswire
-
Acrivon Therapeutics Appoints Jean-Marie Cuillerot, M.D., as Chief Medical Officer
03 Jan 2024 07:00:00 By Nasdaq GlobeNewswire
-
Acrivon Therapeutics to Present at the Piper Sandler Annual Healthcare Conference
21 Nov 2023 07:00:00 By Nasdaq GlobeNewswire
-
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
21 Nov 2023 07:00:00 By Nasdaq GlobeNewswire
-
Acrivon Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights
09 Nov 2023 07:01:00 By Nasdaq GlobeNewswire
-
Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
28 Sep 2023 15:05:00 By Nasdaq GlobeNewswire
-
19 Sep 2023 15:32:13 By Nasdaq GlobeNewswire
- <<
- <
- 1
- >